Overall survival (at 36 months) · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower overall survival (at 36 months) compared with standard therapy (moderate certainty).
1 finding from 1 review
Progression‐free survival (PSF) · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower progression‐free survival (at 24 months) compared with standard therapy (moderate certainty).
1 finding from 1 review
Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · people with newly diagnosed multiple myeloma ineligible for transplant
1 finding from 1 review
Mortality within the longest · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower on‐study mortality (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Serious adverse events at longest · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher serious adverse events (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy showed no clear difference in adverse events (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Adverse events: infections (CTCAE grade ≥ 3) (longest available · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher adverse events: infections (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Death (all causes) · women with locally advanced cervical cancer
Hysterectomy (simple or radical) with neoadjuvant chemotherapy probably leads to lower overall survival Median compared with radiotherapy alone (moderate certainty).
1 finding from 1 review
Disease or progression‐free survival Median · women with locally advanced cervical cancer
Hysterectomy (simple or radical) with neoadjuvant chemotherapy showed no clear difference in disease‐ or progression‐free survival Median compared with radiotherapy alone (moderate certainty).
1 finding from 1 review
Quality of life · women with locally advanced cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse events and toxicity · women with locally advanced cervical cancer
Hysterectomy (simple or radical) with neoadjuvant chemotherapy showed no clear difference in severe adverse events and toxicity compared with radiotherapy alone (low certainty).
1 finding from 1 review
Frequent relapses · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in number with frequent relapses by 12 to 24 months compared with 2 months of therapy (moderate certainty).
1 finding from 1 review
Number of children relapsing by 12 to 24 months · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… may leads to lower number of children relapsing by 12 to 24 months compared with 2 months of therapy (low certainty).
1 finding from 1 review
Number with frequent relapses by 12 to 24 months stratified by risk of selection bias: Low risk of selection bias · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in number with frequent relapses by 12 to 24 months stratified by risk… compared with 2 months of therapy (high certainty).
1 finding from 1 review
Number with frequent relapses by 12 to 24 months stratified by risk of bias for allocation concealment: unclear or high risk of bias for allocation bias · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… may leads to lower number with frequent relapses by 12 to 24 months stratified by risk… compared with 2 months of therapy (low certainty).
1 finding from 1 review
Adverse events: psychological disorders · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in adverse events: psychological disorders compared with 2 months of therapy (low certainty).
1 finding from 1 review
Adverse events: hypertension · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in adverse events: hypertension compared with 2 months of therapy (moderate certainty).
1 finding from 1 review
Adverse events: Cushing's syndrome · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in adverse events: Cushing's syndrome compared with 2 months of therapy (moderate certainty).
1 finding from 1 review
Scar improvement (POSAS) (0–10, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring
2 findings from 1 review
Pain (POSAS 0–10, higher score = more severe pain) · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review